


2-22-01  
scv

Patent Application  
Attorney Docket No. PC11862



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Bruce A. Hay, et al.

#4

APPLICATION NO.: 09/747,437

: Examiner:

FILING DATE: December 21, 2000

: Group Art Unit: Not Yet Assigned

TITLE: Somatostatin Antagonists and Agonists  
that Act at the SST Subtype 2 Receptor

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: 1/17/01

  
E. Victor Donahue  
Attorney for Applicant(s)  
Reg. No. 35,492

Pfizer Inc  
Patent Department, 20th Floor  
235 East 42nd Street  
New York, NY 10017-5755  
(212) 733-2739

I hereby certify that this  
correspondence is being deposited  
with the United States Postal Service  
as First Class Mail in an envelope  
addressed to: Assistant Commissioner  
for Patents, Washington, D.C. 20231  
on the 12<sup>th</sup> day of January, 2001  
By Bruce A. Hay